[1] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[2] |
SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang.
Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
|
[3] |
WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng.
Evaluation of drug safety with multicenter real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
|
[4] |
CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Management of compound glycyrrhiza oral solution and recommendations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
|
[5] |
SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui.
Adverse events of abemaciclib in breast cancer patients based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
|
[6] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[7] |
SONG Fuyu, CAO Yi.
Establishment of Key Performance Indicators for Drug Inspection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414.
|
[8] |
YUE Xiaolin, LU Song, ZHANG Lan.
Research in the construction of comprehensive evaluation systems of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 530-535.
|
[9] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[10] |
LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng.
Quality analysis of Guci tablets based on national drug evaluation sampling
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
|
[11] |
GAO Jing, ZHANG Zhuo, YAN Jiayi, GE Yunxuan, MA Zengchun, GAO Yue.
Evaluation of animal models of high altitude qi deficiency and blood stasis syndrome and research progress in therapeutic drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1189-1194.
|
[12] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[13] |
WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao.
Safety of medications for cardiovascular diseases in community clinics
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.
|
[14] |
LU Song, YANG Ping, YANG Li, DONG Xianzhe, ZHANG Lan.
Research progress in human serum albumin injections
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 228-232.
|
[15] |
HUANG Liting, TANG Zaixiang, BAI Lu, SHI Guanhong, JIANG Yiguo.
Adverse reactions of benzodiazepines based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1223-1227.
|